Platform for Next Generation DNA-based Therapies Novel & Proprietary oDNALinear closed DNA, just the sequence of interest: oDNAProject-based adaptors: “drug-like”IP, oDNA for any indication/application Proprietary GMP ManufactureoDNA. Scalable cell-free synthesisNVV. Scalable and reproducible productionPolyplex. Scalable manufacture Novel & Proprietary NVVPolypeptide-based Non-Viral Vectors (NVV)Project-based customization:TropismModulation of physchem propertiesIP, NVV to deliver any oDNA Novel & Proprietary Therapeutic agentsPolyplex (oDNA & NVV): Therapeutic agentAny cargo sizeRe-dosingIP, based on project-based polyplex Our MissionTo provide the next generation of medicines To treat any genetic disease No limit of transgene size Re-dosing Local & systemic delivery Customizable tropism Safer DNA Storage & Handling requirements Scalable GMP production To open new horizons for current therapeutic approaches CAR-Ts MAbs Vaccines Our Vision Non-viral DNA-based Medicines, a novel strategy to overcome current challenges and achieve the mission Keystones to Tyris technological platform Contact us info@tyristx.com News Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies